Flexion Therapeutics (FLXN) Earns Daily News Sentiment Rating of 0.11
News stories about Flexion Therapeutics (NASDAQ:FLXN) have been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Flexion Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 46.8924579548993 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have effected Accern’s rankings:
- Stock’s Risk Factors to Track – Flexion Therapeutics, Inc., (NASDAQ: FLXN) – Stock Watch (stocksnewstimes.com)
- That Will Motivate You Today– Flexion Therapeutics, Inc. (NASDAQ:FLXN) – The Stock Street (press release) (thestreetpoint.com)
- Flexion Therapeutics (FLXN) Names Scott Kelley, MD as Chief Medical Officer – StreetInsider.com (streetinsider.com)
- Notable Monday Option Activity: KHC, RGLD, FLXN (nasdaq.com)
- Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer (finance.yahoo.com)
Flexion Therapeutics (NASDAQ FLXN) opened at $24.82 on Wednesday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 12.93 and a current ratio of 12.93. Flexion Therapeutics has a 1 year low of $16.51 and a 1 year high of $32.25.
In other news, insider Michael D. Clayman bought 5,000 shares of the stock in a transaction dated Wednesday, November 8th. The stock was bought at an average price of $23.60 per share, for a total transaction of $118,000.00. Following the completion of the acquisition, the insider now directly owns 35,395 shares in the company, valued at approximately $835,322. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Neil Bodick bought 2,700 shares of the stock in a transaction dated Tuesday, November 21st. The stock was purchased at an average price of $24.49 per share, with a total value of $66,123.00. Following the acquisition, the insider now owns 64,605 shares of the company’s stock, valued at $1,582,176.45. The disclosure for this purchase can be found here. Corporate insiders own 15.98% of the company’s stock.
WARNING: “Flexion Therapeutics (FLXN) Earns Daily News Sentiment Rating of 0.11” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2017/12/13/flexion-therapeutics-flxn-earns-daily-news-sentiment-rating-of-0-11.html.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.